Search results
Q2 2024 EPS Estimates for Longboard Pharmaceuticals, Inc. Cut by Analyst (NASDAQ:LBPH)
ETF DAILY NEWS· 7 hours agoLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Free Report) – Equities research analysts at B. Riley dropped their Q2 2024 EPS estimates for Longboard Pharmaceuticals ...
Insider Sale: Director Julie Mchugh Sells Shares of Ironwood Pharmaceuticals Inc (IRWD)
GuruFocus.com via Yahoo Finance· 1 day agoFollowing this transaction, the insider now owns 139,528 shares of Ironwood Pharmaceuticals Inc....
Lilly’s Weight-Loss Drug Is a Huge Hit. Its CEO Wants to Replace It ASAP.
The Wall Street Journal· 6 hours agoJust a year and a half later, it was approved as Zepbound for chronic weight management. “I’m pretty...
NHS and ABPI announce new guidelines ahead of UK elections
Pharmaceutical Technology via Yahoo Finance· 14 hours agoIt highlights how partnerships can be formed between local NHS organisations and the pharmaceutical...
Cranbury Pharmaceuticals Receives FDA Approval for First Generic Version of Emflaza Oral Suspension
New Jersey Business Magazine· 1 day agoCranbury Pharmaceuticals, a wholly-owned subsidiary of Tris Pharma, today announced the U.S. Food...
A New Drug Could Slow Alzheimer's. But Can Patients Get It?
Bloomberg· 2 days agoA New Drug Could Slow Alzheimer's. But Can Patients Get It? A new medicine from Eli Lilly will face...
Longboard Pharmaceuticals (NASDAQ:LBPH) Stock Rating Reaffirmed by HC Wainwright
ETF DAILY NEWS· 1 day agoLongboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued ...
Brokers Offer Predictions for Longboard Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:LBPH)
ETF DAILY NEWS· 1 day agoLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Free Report) – Stock analysts at Wedbush issued their Q1 2025 earnings estimates for shares of Longboard Pharmaceuticals ...
African institutions and USP announce free access to resources to support production of quality...
FOX 5 San Diego· 1 day agoThe United States Pharmacopeia National Formulary (USP-NF) and the USP Education...
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,229.00
ETF DAILY NEWS· 1 day agoRegeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price upped by Royal Bank of Canada from $1,200.00 to $1,229.00 in a research report sent to investors ...